Bio Green Med Solution, Inc.

Regulatory Filings • Jul 24, 2025

CORRESP 1 filename1.htm

CYCLACEL PHARMACEUTICALS, INC.

Level 10, Tower 11, Avenue 5, The Horizon

Bangsar South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia

July 24, 2025

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

via EDGAR

RE: Cyclacel Pharmaceuticals, Inc. (CIK0001130166)

Registration Statement on Form S-4

Filed: July 24, 2025

Securities Act File No.: 333-288912

Request for Acceleration of Effectiveness

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests acceleration of its Registration Statement on Form S-4 (File No. 333-288912), filed on July 24, 2025, so that it will become effective at 5:00 p.m. (Eastern time) on July 25, 2025, or as soon as practicable thereafter.

If you have any questions, or require any additional information, please do not hesitate to email Debbie Klis, the Registrant’s outside counsel, at debbie.klis@rimonlaw.com or phone on 202-935-3390.

| Very
truly yours, | |
| --- | --- |
| Cyclacel
Pharmaceuticals, Inc. | |
| By: | /s/
Datuk Dr. Doris Wong |
| | Datuk
Dr. Doris Wong |
| | Chief
Executive Officer |

Field: Page; Sequence: 1; Options: Last

Field: /Page